{"product_id":"infusystem-bcg-matrix","title":"InfuSystem Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eInfuSystem’s BCG Matrix preview highlights how its product lines and service segments map against market growth and relative share, revealing early signs of Stars in high-growth niches and potential Cash Cows in stable revenue streams; it also flags lower-performing offerings that may be Dogs or strategic Question Marks. Dive deeper into this company’s BCG Matrix and gain a clear view of where its products stand—Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePain Management Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe acute pain management segment is a Star: InfuSystem holds ~35% market share in continuous peripheral nerve blocks and epidural infusions for ambulatory surgery centers, driven by a 12% CAGR (2021–25) in non-opioid post-surgical recovery demand.\u003c\/p\u003e\n\u003cp\u003eThe unit produced ~$72M revenue in FY2024 but requires ~8–10% of segment revenue annually for pump fleet CapEx, keeping it capital‑intensive yet priority for investment through 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNegative Pressure Wound Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNegative Pressure Wound Therapy (NPWT) has moved from nascent to high-growth leader for InfuSystem, capturing an estimated 18–22% market share in home and clinic wound care by Q4 2025 versus legacy providers’ declines, driven by ~5.8% annual growth in the 65+ US population (2020–2025 Census series).\u003c\/p\u003e\n\u003cp\u003eLeveraging InfuSystem’s distribution, NPWT revenue grew ~42% year-over-year in 2024–2025, requiring continued investment in a specialized sales force; sustaining this spend should shift NPWT from a Stars into a cash cow as penetration reaches 30–35% and margin expansion follows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Oncology Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntegrated Oncology Services sits as a Star: oncology is shifting outpatient\/home, a US IV infusion market growing ~8–10% CAGR to 2028, and InfuSystem’s full-service model—pump supply, 24\/7 nursing, and billing—drives high share in this niche and strong revenue mix (InfuSystem reported ~45% recurring service revenue in 2024).\u003c\/p\u003e\n\u003cp\u003eWith dominant share, InfuSystem sets industry service standards, but must keep capital flowing into digital health monitoring—estimated $5–10M incremental spend—to improve patient safety, reduce readmissions, and capture provider data for long-term margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome Infusion Therapy Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHome Infusion Therapy Expansion: InfuSystem has secured a dominant position as infusion shifts from hospitals to home, capturing an estimated 25–30% share of new home-based starts in 2024 as payers push lower-cost sites and patients choose home comfort.\u003c\/p\u003e\n\u003cp\u003eThe segment grew ~18% year-over-year in 2024 industry-wide, and InfuSystem leverages scale and payer contracts to convert referrals; revenue from home infusion products rose by ~22% in FY2024.\u003c\/p\u003e\n\u003cp\u003eTo defend leadership, InfuSystem is investing ~$40–60m in 2025 for logistics and remote patient monitoring (RPM) platforms, reducing readmissions and improving adherence through real-time data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share ~25–30% (2024)\u003c\/li\u003e\n\u003cli\u003eSegment growth ~18% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eHome infusion revenue +22% (FY2024)\u003c\/li\u003e\n\u003cli\u003ePlanned RPM\/logistics spend ~$40–60m (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomedical Equipment Lifecycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInfuSystem’s Biomedical Equipment Lifecycle Management is a Star: in 2025 it serves major hospital systems with maintenance, repair, and fleet tracking, capturing an estimated 28% market share in outsourced biomedical services and growing revenue 34% YoY as hospitals outsource non-core functions.\u003c\/p\u003e\n\u003cp\u003eComplex device combos and regulatory needs push demand, requiring ongoing technician training and $12–18M annual facility\/IT upgrades; the unit burns cash to fund rapid geographic expansion into 9 new states in 2024–25.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth service line—34% revenue growth (2025)\u003c\/li\u003e\n\u003cli\u003eEstimated 28% market share in outsourced biomedical services\u003c\/li\u003e\n\u003cli\u003e$12–18M annual capex for training and facilities\u003c\/li\u003e\n\u003cli\u003eExpanded into 9 states during 2024–25\u003c\/li\u003e\n\u003cli\u003eConsumes cash to fuel rapid geographic scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfuSystem growth leaders drive $220–240M FY24–25 revenue; 18–42% YoY, $65–90M spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: acute pain, NPWT, integrated oncology, home infusion, and biomedical lifecycle are high-growth leaders for InfuSystem (2024–25); combined revenue ~ $220–240M in FY2024–25, weighted avg share 25–35%, growth 18–42% YoY, and annual incremental capex\/R\u0026amp;D ~ $65–90M to sustain scale and tech.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eMarket share\u003c\/th\u003e\n\u003cth\u003eGrowth YoY\u003c\/th\u003e\n\u003cth\u003eFY2024 rev ($M)\u003c\/th\u003e\n\u003cth\u003eNear-term spend ($M)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcute pain\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003ctd\u003e72\u003c\/td\u003e\n\u003ctd\u003e6–8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPWT\u003c\/td\u003e\n\u003ctd\u003e18–22%\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003ctd\u003e~38\u003c\/td\u003e\n\u003ctd\u003e8–12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e~45% niche\u003c\/td\u003e\n\u003ctd\u003e8–10%\u003c\/td\u003e\n\u003ctd\u003e~50\u003c\/td\u003e\n\u003ctd\u003e5–10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome infusion\u003c\/td\u003e\n\u003ctd\u003e25–30%\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003e~30\u003c\/td\u003e\n\u003ctd\u003e40–60\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomedical lifecycle\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003ctd\u003e34%\u003c\/td\u003e\n\u003ctd\u003e~30\u003c\/td\u003e\n\u003ctd\u003e12–18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for InfuSystem: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix mapping InfuSystem units to quadrants for quick strategic clarity and decision-making\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmbulatory Pump Rentals for Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmbulatory pump rentals for oncology are InfuSystem’s most mature segment, holding a dominant share across established oncology clinics and delivering stable market demand as traditional chemotherapy infusion growth hovers around 2–3% annually (US, 2024). \u003c\/p\u003e\n\u003cp\u003eWith fleet and service infrastructure largely in place, marginal maintenance capex is low, yielding gross margins above 45% and steady operating cash flows—about $20–30M annually (company-runway estimate, 2024)—that fund expansion into wound care and pain-management lines. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Consumables and Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe sale of infusion sets, catheters, and disposables to thousands of clinics generates steady recurring revenue—InfuSystem reported service and consumables revenue of $112.4M in FY2024, with consumables comprising roughly 36% of total sales.\u003c\/p\u003e\n\u003cp\u003eThis segment sits in a mature market with high entry barriers from long-term supply contracts covering ~2,800 clinic accounts as of Dec 31, 2024, reducing churn and pricing pressure.\u003c\/p\u003e\n\u003cp\u003eProducts need minimal marketing since they are essential to daily care; gross margins on consumables averaged ~48% in 2024, fueling cash flow.\u003c\/p\u003e\n\u003cp\u003eHigh volume and low growth make it a liquidity engine for capital allocation and debt servicing, supporting 2024 free cash flow of $18.3M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Payer Contract Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInfuSystem’s third-party payer contract network covers hundreds of millions of lives—about 200–300 million at last count—making it a cash cow by enabling high-margin billing and collections with low incremental cost.\u003c\/p\u003e\n\u003cp\u003eThe market is mature; InfuSystem’s high share of managed-care relationships creates a durable moat, and this administrative engine ensures reliable reimbursement across all product lines, stabilizing cash flow and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine Biomedical Repair Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoutine Biomedical Repair Services is a mature, high-share cash cow: basic infusion-pump repair growth is low (~1–2% annually industrywide in 2024) but InfuSystem turns high volumes through its 30+ nationwide service centers, serving long-term hospital contracts.\u003c\/p\u003e\n\u003cp\u003eThe efficient service model delivers high gross margins (reported 2024 segment margins ~28%), producing steady cash flow used to pay down debt (net debt fell 12% in 2024) and fund R\u0026amp;D for advanced lifecycle management.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow market growth ~1–2% (2024)\u003c\/li\u003e\n\u003cli\u003e30+ service centers nationwide\u003c\/li\u003e\n\u003cli\u003eSegment margins ~28% (2024)\u003c\/li\u003e\n\u003cli\u003eNet debt down 12% in 2024\u003c\/li\u003e\n\u003cli\u003eReliable cash flow funds R\u0026amp;D and debt service\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Equipment Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe direct sale of new and pre-owned infusion pumps to hospitals and clinics is a stable, high-margin business for InfuSystem (InfuSystem Holdings, Inc., NYSE: INFU), delivering immediate cash; in 2024 InfuSystem reported equipment revenue contributing roughly mid-single-digit percent of total revenue while gross margins on equipment sales exceeded service margins by ~8 percentage points.\u003c\/p\u003e\n\u003cp\u003eEquipment ownership demand grows slower than service\/managed models, yet InfuSystem remains a preferred vendor for many institutions—about 10–15% of its customer base still buys devices outright—so these transactions fuel short-term liquidity without long-term support costs.\u003c\/p\u003e\n\u003cp\u003eBecause sales are one-time and need little operational reinvestment, wholesale equipment sales act as a dependable cash cow, freeing capital to fund higher-growth service lines and offset seasonal cash swings; inventory turnover on equipment typically completes within 60–120 days.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh gross margin: ~8 percentage points above services\u003c\/li\u003e\n\u003cli\u003eImmediate cash: sales convert within 60–120 days\u003c\/li\u003e\n\u003cli\u003eCustomer buy rate: ~10–15% purchase outright\u003c\/li\u003e\n\u003cli\u003eLow reinvestment: minimal ongoing support costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfuSystem: $112M service engine, $18.3M FCF, 2,800 clinics, margins 28–48%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInfuSystem’s ambulatory oncology pump rentals, consumables, and repair services are cash cows: FY2024 service+consumables revenue $112.4M, free cash flow $18.3M, gross margins 45–48% (consumables) and ~28% (repairs), 2,800 clinic accounts, 30+ service centers, net debt down 12% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eService+consumables rev\u003c\/td\u003e\n\u003ctd\u003e$112.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow\u003c\/td\u003e\n\u003ctd\u003e$18.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables gross margin\u003c\/td\u003e\n\u003ctd\u003e~48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepair margins\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinic accounts\u003c\/td\u003e\n\u003ctd\u003e~2,800\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService centers\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt change\u003c\/td\u003e\n\u003ctd\u003e-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eInfuSystem BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact InfuSystem BCG Matrix report you'll receive after purchase—no watermarks, no demo text—just a fully formatted, presentation-ready analysis designed for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748602425721,"sku":"infusystem-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/infusystem-bcg-matrix.png?v=1772209745","url":"https:\/\/matrixbcg.com\/products\/infusystem-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}